Biocon to market new breast cancer drug in IndiaJuly 18th, 2008 - 10:11 pm ICT by IANS
Bangalore, July 18 (IANS) Biotechnology major Biocon Ltd will market Abraxane drug of the US-based Abraxis BioScience in India for treating breast cancer, a top company official said here Friday. To be priced at about $400 (Rs.17,200) per 100mg vial in India, the drug will be cheaper by 60 percent than in the US where it is sold at $1,000 (Rs.43,000) per vial of same measure.
Abraxane will be the second oncotherapeutics drug Biocon will be marketing after the launch of its proprietary antibody Biomab for the treatment of head and neck cancers.
“Abraxane is the first albumin-bound taxane particle of 130 nanometres that takes advantage of albumin, a natural carrier of water-insoluble molecules found in human beings,” Biocon chairperson Kiran Mazumdar-Shaw told reporters at a preview of the innovative product.
The scheduled drug is being introduced for the first time in India for treating breast cancer after the failure of combination therapy for metastatic disease or relapse of adjuvant chemotherapy within six months.
As a protein, albumin acts as the body’s key transporter of nutrients and other water-soluble molecules and selectively accumulates in tumour tissues.
Abraxane was approved by the US Food and Drug Administration (FDA) in 2005 and the Drug Controller General of India in 2007 on the basis of clinical trial data, which demonstrated that the drug doubled the response rate, prolonging life and improved survival rate of breast cancer patients.
“With about 100,000 cases of breast cancer detected in Indian women every year, the dreaded disease has emerged as the second largest cause of death among women in the country” Shaw said.
“Studies reveal about 45,000 Indian women die of breast cancer every year. With one in 22 cancer cases being identified as breast cancer, the disease is increasing by 8-10 percent every year.”
Unlike conventional breast cancer drugs such as Taxol and Taxotere, Abraxane eliminates the need for chemical solvents and allows for higher doses of paclitaxel protein-based particles for injectable suspension without compromising safety and tolerability.
“The launch of Abraxane provides breakthrough therapeutics to cancer patients in India, which is safe, effective and affordable. Besides India, we will be marketing the drug in 10 other countries after securing regulatory approvals,” Shaw said.
Pakistan, Bangladesh, Sri Lanka, the United Arab Emirates (UAE), Saudi Arabia, Kuwait and some South Asian countries are the targeted markets.
“Though cancer rates in India are lower than those in western countries, the cases are rising due to early detection and increasing migration of rural population to cities, increasing life expectancy and changing lifestyles.
“The breast is the second most common site in women after the cervix uteri. In metros like Delhi and Mumbai, breast cancer is the most common kind of disease in women,” Shaw said.
- India, China making inroads in biotech drugs: NYT - Sep 19, 2011
- India-Cuba joint discovery in biomedical sciences wins award - Jul 19, 2011
- Biocon launches anti-cancer drug in Abu Dhabi - Oct 10, 2008
- Biocon unveils India's first 24-hour diabetes drug - May 29, 2009
- New therapy shows promising result for HER2-positive metastatic disease - Oct 09, 2010
- Biocon ties up with Pfizer to market biosimilars - Oct 18, 2010
- Breast cancer cases in India to double by 2015: Experts - Oct 19, 2011
- Pfizer snaps insulin marketing deal with Biocon - Mar 13, 2012
- Biocon, US firm to jointly make drug for diabetes - Sep 11, 2009
- Silencing 'hedgehog' molecule halts cancer - Jun 06, 2011
- Breast cancer is a major killer in Pakistan - Jan 12, 2012
- Women in urban areas more prone to breast cancer - Oct 06, 2010
- Awareness key to beating breast cancer, say experts (Feb 4 is World Cancer Day) - Feb 03, 2012
- India witnessing rise in pancreatic cancer, say doctors - Oct 06, 2011
- Drug used to treat asthma 'prevents spread of breast cancer' - Nov 04, 2010
Tags: abraxane, albumin, biocon ltd, breast cancer, breast cancer drug, breast cancer drugs, breast cancer patients, cancer cases, combination therapy, controller general, food and drug administration, food and drug administration fda, india bangalore, innovative product, kiran mazumdar shaw, neck cancers, soluble molecules, survival rate of breast cancer, time in india, us food and drug administration